A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma

LESSONS LEARNED. Pazopanib shows a modest efficacy in metastatic alveolar soft part sarcoma. Clinical outcomes were comparable to those in previous studies using antiangiogenic drugs. Further prospective studies evaluating the benefit of pazopanib in alveolar soft part sarcoma with a larger sample a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Kim, Miso, Kim, Tae Min, Keam, Bhumsuk, Kim, Yu Jung, Paeng, Jin Chul, Moon, Kyung Chul, Kim, Dong‐Wan, Heo, Dae Seog
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2018
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324645/
https://ncbi.nlm.nih.gov/pubmed/30254189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0464
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky